کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2138277 | 1087872 | 2010 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma-A report by the Polish Myeloma Study Group
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
This study included 132 untreated and relapsing/resistant patients treated with the low-thalidomide dose CTD regimen. The patients received CY 500Â mg/m2i.v. or 625Â mg/m2 orally at day 1, THAL 100Â mg/day á la longue and DEX 20Â mg/day at days 1-4 and 8-11, every 28 days. Patients received 6-9 cycles; ORR by 3 months was 59.1%, by 6 months 65.6% and by 9 months 75.6%. In patients responding to CTD therapy (CR, nCR, PR), the probability of survival for 20 months was 89.3%. The outpatient low-thalidomide dose CTD regimen is well tolerated and produces a significant response rate both in untreated and relapsing/resistant MM patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 34, Issue 10, October 2010, Pages 1330-1335
Journal: Leukemia Research - Volume 34, Issue 10, October 2010, Pages 1330-1335
نویسندگان
Anna Dmoszynska, Adam Walter-Croneck, Iwona Hus, Norbert Grzasko, Joanna Manko, Wieslaw Wiktor Jedrzejczak, Grzegorz Charlinski, Lidia Usnarska-Zubkiewicz, Aleksander Skotnicki, Teresa Wolska-Smolen, Jaroslaw Piszcz, Janusz Kloczko,